SCHEMBL25948851

SCHEMBL25948851

Cc1cn2c(C)ccc2c(C)n1

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PTPN1 P18031 3/20 0.37
PTPN2 P17706 1/20 0.37
ADORA3 P0DMS8 2/20 0.32
ADORA2A P29274 1/20 0.32
TNKS O95271 1/20 0.30
PARP1 P09874 1/20 0.30
SLC6A3 Q01959 1/20 0.30
PARP6 Q2NL67 1/20 0.30
PARP10 Q53GL7 1/20 0.30
TIPARP Q7Z3E1 1/20 0.30
PARP8 Q8N3A8 1/20 0.30
PARP12 Q9H0J9 1/20 0.30
TNKS2 Q9H2K2 1/20 0.30
PARP11 Q9NR21 1/20 0.30
PARP2 Q9UGN5 1/20 0.30
PARP3 Q9Y6F1 1/20 0.30
KDM4E B2RXH2 1/20 0.30
MAPT P10636 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13483977 0.79 PTPN1 (0.35) PTPN1PTPN2KDM4E
SCHEMBL7947747 0.65 GAA (0.50) KDM4EMAPT
SCHEMBL13556611 0.65 PTPN2 (0.33) PTPN1PTPN2
SCHEMBL25948848 0.64 CDK4 (0.33)
SCHEMBL13153126 0.64 GRM5 (0.54) PTPN1PTPN2KDM4E
SCHEMBL22054405 0.64 PIK3C3 (0.36) PTPN1PTPN2KDM4E
SCHEMBL25948854 0.64 FNTA (0.38) ADORA3TNKSPARP1SLC6A3PARP6
SCHEMBL18747055 0.63 PARP10 (0.61) TNKSPARP1PARP10TIPARPPARP12
SCHEMBL19576040 0.63 ADORA2A (0.34) ADORA3ADORA2AKDM4E
SCHEMBL20448940 0.63 GAA (0.46) PTPN1PTPN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230242533-A9 SUBSTITUTED FUSED HETEROAROMATIC BICYCLIC COMPOUNDS AS KINASE INHIBITORS AND THE USE THEREOF Impact Therapeutics (Shanghai), Inc (CN) 2023-08-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230242533-A9 SUBSTITUTED FUSED HETEROAROMATIC BICYCLIC COMPOUNDS AS KINASE INHIBITORS AND THE USE THEREOF ATR, CHEK1, CHEK2 PTPN1 2003/4885PTPN2 2608/4885ADORA3 1827/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.